Read by QxMD icon Read

Radiotherapy clinical trial

Winan J van Houdt, Chandrajit P Raut, Sylvie Bonvalot, Carol J Swallow, Rick Haas, Alessandro Gronchi
PURPOSE OF REVIEW: Retroperitoneal sarcoma (RPS) is a rare disease, and until recently, its natural history and outcome were poorly understood. Recently, collaborations between individual centers have led to an unprecedented collection of retrospective and prospective data and successful recruitment to the first randomized trial as described here. RECENT FINDINGS: A debate about the beneficial role of extended surgery in RPS triggered an initial collaboration between Europe and North America, the TransAtlantic RetroPeritoneal Sarcoma Working Group (TARPSWG)...
March 15, 2019: Current Opinion in Oncology
Natalia Gutteck, Sebastian Schilde, Karl-Stefan Delank
BACKGROUND: Plantar fasciitis (PF) is characterized by pain on weight-bearing in the medial plantar area of the heel, metatarsalgia (MTG) by pain on the plantar surface of the forefoot radiating into the toes. Reliable figures on lifetime prevalence in Germany are lacking. METHODS: This review is based on pertinent publications retrieved from a selective search in PubMed, on guidelines from Germany and abroad, and on the authors' clinical experience. RESULTS: Plantar fasciitis is generally diagnosed from the history and physical examination, without any ancillary studies...
February 8, 2019: Deutsches Ärzteblatt International
Michael McCarthy, Roslyn Francis, Colin Tang, Joanne Watts, Andrew Campbell
AIM: This study is to assess the utility of68 Gallium PSMA HBED-CC PET/CT (PSMA-HBED), compared to standard imaging, in the detection of recurrent prostate carcinoma in patients with biochemical relapse, to determine the prevalence of oligometastatic disease recurrence and its distribution. METHOD: This is a prospective, multicentre clinical trial of PSMA-HBED PET/CT imaging in patients with early biochemical relapse of prostate carcinoma (PCa) (median PSA 2.55ng/ml) following definitive prostatectomy (152 patients) or radiotherapy (86 patients) with either no lesions or oligometastatic disease on abdominopelvic CT (CT) and bone scan (BS)...
March 16, 2019: International Journal of Radiation Oncology, Biology, Physics
Eva Clemens, Annelot Jm Meijer, Linda Broer, Thorsten Langer, Anne-Lotte Lf van der Kooi, André G Uitterlinden, Andrica de Vries, Claudia E Kuehni, Maria L Garrè, Tomas Kepak, Jarmila Kruseova, Jeanette F Winther, Leontien C Kremer, Eline van Dulmen-den Broeder, Wim Je Tissing, Catherine Rechnitzer, Line Kenborg, Henrik Hasle, Desiree Grabow, Ross Parfitt, Harald Binder, Bruce C Carleton, Julianne Byrne, Peter Kaatsch, Antoinette Am Zehnhoff-Dinnesen, Oliver Zolk, Marry M van den Heuvel-Eibrink
BACKGROUND: Survival rates after childhood cancer now reach nearly 80% in developed countries. However, treatments that lead to survival and cure can cause serious adverse effects with lifelong negative impacts on survivor quality of life. Hearing impairment is a common adverse effect in children treated with cisplatin-based chemotherapy or cranial radiotherapy. Ototoxicity can extend from high-tone hearing impairment to involvement of speech frequencies. Hearing impairment can impede speech and language and neurocognitive development...
March 19, 2019: JMIR Research Protocols
George U Eleje, Ahizechukwu C Eke, Gabriel O Igberase, Anthony O Igwegbe, Lydia I Eleje
BACKGROUND: This is an updated version of the original Cochrane review published in Issue 5, 2015.Cervical cancer is the fourth most common cancer among women worldwide, with estimated 569,847 new diagnoses and 311,365 deaths per year. However, incidence and stage at diagnosis vary greatly between geographic areas and are largely dependent on the availability of a robust population screening programme. For example, in Nigeria, advanced-stage disease at presentation is common (86% to 89...
March 19, 2019: Cochrane Database of Systematic Reviews
Omar Abdel-Rahman
AIM: To assess whether clinical trial participation affects survival outcomes of radiotherapy-treated localized prostate cancer patients compared with similar treatment within a real-world setting. METHODS: This is a comparative analysis of the outcomes of localized prostate cancer patients treated within two clinical trials (NCT00331773; NCT00004054) versus the outcomes of similar cohorts of patients registered within the SEER database and treated with radiotherapy...
March 19, 2019: Future Oncology
Nikolaos Tselis, Georgios Chatzikonstantinou
Purpose: To review the role of radiotherapy (RT) in the treatment of renal cell cancer (RCC) in the curative and palliative setting. Content: Details related to the clinical outcomes of primary, preoperative, postoperative and palliative RT are discussed, along with a presentation of the established role of surgery and systemic therapy. An overview of data derived from mono- and multi-institutional trials is provided. Conclusion: Radiotherapy has been shown to provide good symptom palliation and local control in RCC depending on the dose that can be delivered...
May 2019: Clinical and Translational Radiation Oncology
Alexandra K Walker, Katalin Karaszi, Helen Valentine, Victoria Y Strauss, Ananya Choudhury, Shaun McGill, Kaisheng Wen, Michael D Brown, Vijay Ramani, Selina Bhattarai, Mark Tw Teo, Lingjian Yang, Kevin A Myers, Nayneeta Deshmukh, Helen Denley, Lisa Browning, Sharon B Love, Gopa Iyer, Noel W Clarke, Emma Hall, Robert Huddart, Nicholas D James, Peter J Hoskin, Catharine Ml West, Anne E Kiltie
PURPOSE: Organ-confined muscle-invasive bladder cancer (MIBC) is treated with cystectomy or bladder preservation techniques, including radiotherapy. There are currently no biomarkers to inform management decisions and aid patient choice. Previously we showed high levels of MRE11 protein, assessed by immunohistochemistry (IHC), predicted outcome following radiotherapy but not cystectomy. Therefore, we sought to develop the MRE11 IHC assay for clinical use and define its relationship to clinical outcome in samples from two major clinical trials...
March 15, 2019: International Journal of Radiation Oncology, Biology, Physics
Tiberiu Popescu, Ulf Karlsson, Vincent Vinh-Hung, Lurdes Trigo, Juliette Thariat, Te Vuong, Brigitta G Baumert, Micaela Motta, Alice Zamagni, Marta Bonet, Arthur Sun Myint, Pedro Carlos Lara, Nam P Nguyen, Meritxell Arenas
The management of older cancer patients remains difficult because of data paucity. Radiation oncologists need to identify potential issues which could affect treatment of those patients. A workshop was organized in Barcelona among international radiation oncologists with special interest in the management of older cancer patients on April 22, 2018. The following consensus was reached: 1. Older cancer patients often faced unconscious discriminating bias from cancer specialists and institutions because of their chronological age...
March 16, 2019: Cancers
Luyao Wang, Ruixue Yao, Lifa Zhang, Chuanbo Fan, Leina Ma, Jia Liu
Chimeric antigen receptor T (CAR-T) cell therapy provides possibility for the treatment of malignancies since clinical trials have shown that CAR-T therapy has a significant anti-tumor effect. Although many efforts have been made to improve the efficacy and reduce the side effects of CAR-T therapy, there are still many problems to solve. With the rapid development of this field, combination immunotherapy has been proved to improve the efficacy of CAR-T therapy. Studies have shown that radiotherapy, chemotherapy, oncolytic virotherapy, BTK inhibitors and immune checkpoint blockade-based therapy may further enhance the efficacy of CAR-T therapy while CRISPR/Cas9 technology and IL-1 blockade may improve the safety...
March 12, 2019: International Immunopharmacology
Maxime J M van der Valk, Denise E Hilling, Elma Meershoek-Klein Kranenbarg, Koen C M J Peeters, Ellen Kapiteijn, Roula Tsonaka, Cornelis J H van de Velde, Perla J Marang-van de Mheen
BACKGROUND: Adjuvant chemotherapy after curative resection for rectal cancer is the standard of care in several American and European guidelines. OBJECTIVE: The aim of this study was to examine the differences in health-related quality of life over time between patients with rectal cancer who were treated with adjuvant chemotherapy or observation. DESIGN: This is a randomized controlled phase III trial. SETTINGS: Health-related quality-of-life assessments were conducted in Dutch patients from 43 institutes...
March 11, 2019: Diseases of the Colon and Rectum
Nikolaos F Pistamaltzian, Vassilis Georgoulias, Athanasios Kotsakis
Cancer immunotherapy represents a major therapeutic breakthrough. Immune checkpoint inhibitors alone or in the context of a combination are considered the new standard of care in advanced non-small cell lung cancer (NSCLC). Areas covered: This review explains the biologic rationale behind the implementation of immune checkpoint inhibitors for the therapy of advanced NSCLC. It provides a detailed description of the clinical trials that have studied the various agents now in use and the results that lead to the currently approved indications...
March 14, 2019: Expert Review of Respiratory Medicine
Pierre Vera, Sorina-Dana Mihailescu, Justine Lequesne, Romain Modzelewski, Pierre Bohn, Sébastien Hapdey, Louis-Ferdinand Pépin, Bernard Dubray, Philippe Chaumet-Riffaud, Pierre Decazes, Sébastien Thureau
PURPOSE: Chemoradiotherapy is the reference curative-intent treatment for nonresectable locally advanced non-small-cell lung carcinoma (NSCLC), with unsatisfactory survival, partially due to radiation resistance in hypoxic tissues. The objective was to update survival and toxicity at 3 years following radiotherapy boost to hypoxic tumours in NSCLC patients treated with curative-intent chemoradiotherapy. METHODS: This was an open-label, nonrandomized, multicentre, phase II clinical trial...
March 13, 2019: European Journal of Nuclear Medicine and Molecular Imaging
Christopher M Waldmann, Andreea D Stuparu, R Michael van Dam, Roger Slavik
The trend to inform personalized molecular radiotherapy with molecular imaging diagnostics, a concept referred to as theranostics, has transformed the field of nuclear medicine in recent years. The development of theranostic pairs comprising somatostatin receptor (SSTR)-targeting nuclear imaging probes and therapeutic agents for the treatment of patients with neuroendocrine tumors (NETs) has been a driving force behind this development. With the Neuroendocrine Tumor Therapy (NETTER-1) phase 3 trial reporting encouraging results in the treatment of well-differentiated, metastatic midgut NETs, peptide radioligand therapy (RLT) with the 177 Lu-labeled somatostatin analog (SSA) [177 Lu]Lu-DOTA-TATE is now anticipated to become the standard of care...
2019: Theranostics
Rimas V Lukas, Derek A Wainwright, Erik Ladomersky, Sean Sachdev, Adam M Sonabend, Roger Stupp
Glioblastoma is an aggressive primary tumor of the central nervous system. This review will focus on clinical developments and management of newly diagnosed disease, including a discussion about the incorporation of molecular features into the classification of glioblastoma. Such advances will continue to shape our thinking about the disease and how to best manage it. With regards to treatment, the role of surgical resection, radiotherapy, chemotherapy, and tumor-treating fields will be presented. Pivotal studies defining our current standard of care will be highlighted, as will key ongoing trials that may influence our management of glioblastoma in the near future...
March 13, 2019: Oncology (Williston Park, NY)
Alexandre Bozec, Dorian Culié, Gilles Poissonnet, Olivier Dassonville
PURPOSE OF REVIEW: The objective of this review article is to discuss the current role of surgery as the primary treatment modality in patients with head and neck squamous cell carcinoma (HNSCC). RECENT FINDINGS: HNSCC represents one of the cancer locations where the primary treatment modality is the most under discussion. Indeed, the respective roles of primary surgical resection followed, as necessary, by adjuvant radiotherapy or definitive chemoradiotherapy remain controversial...
March 8, 2019: Current Opinion in Oncology
Zhenzhen Yin, Jinqiang You, Youyou Wang, Jinlin Zhao, Shengpeng Jiang, Ximei Zhang, Peiguo Wang, Zhen Tao, Xin Wang, Zhiyong Yuan
Purpose: To determine the efficacy and late toxicities of moderate (2.5-4 Gy) hypofractionated radiotherapy (H-RT) in localized prostate cancer, a meta-analysis of published randomized clinical trials comparing moderate H-RT with conventional fractionated RT (C-RT) was performed. Materials and methods: Systematic search on published randomized clinical trials in English according to Cochrane review guidelines in databases of Pubmed, Embase, Cochrane, web of science, and Wiley Online Library was carried out...
2019: OncoTargets and Therapy
Peng Song, Jingcheng Zhang, Congcong Shang, Li Zhang
To summarize the therapeutic effects of PD-1/PD-L1 inhibitors on patients with advanced non-small cell lung cancer (NSCLC) in a real-world setting, we attempted to identify potential molecular biomarkers or clinical factors that reflected the therapeutic effect. The medical records of patients with non-small cell lung cancer who were treated with PD-1/PD-L1 inhibitors were obtained from the outpatient department or inpatient department of Peking Union Medical College Hospital from August 1, 2015, to January 1, 2018...
March 12, 2019: Scientific Reports
E Shelley Hwang, Terry Hyslop, Thomas Lynch, Elizabeth Frank, Donna Pinto, Desiree Basila, Deborah Collyar, Antonia Bennett, Celia Kaplan, Shoshana Rosenberg, Alastair Thompson, Anna Weiss, Ann Partridge
INTRODUCTION: Ductal carcinoma in situ (DCIS) is a non-invasive non-obligate precursor of invasive breast cancer. With guideline concordant care (GCC), DCIS outcomes are at least as favourable as some other early stage cancer types such as prostate cancer, for which active surveillance (AS) is a standard of care option. However, AS has not yet been tested in relation to DCIS. The goal of the COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial for low-risk DCIS is to gather evidence to help future patients consider the range of treatment choices for low-risk DCIS, from standard therapies to AS...
March 12, 2019: BMJ Open
Pietro Delia, Giuseppe Sansotta, Antonio Pontoriero, Giuseppe Iati, Santa De Salvo, Michele Pisana, Antonio Potami, Salvatore Lopes, Giovanna Messina, Stefano Pergolizzi
BACKGROUND: Radiotherapy treatment for cervical cancer (CC) often induces side effects, including inflammation, dryness, dyspareunia. Considering its key role in the healing process, hyaluronic acid (HA) could be useful for the completion of radiotherapy. OBJECTIVES: The aim of this work was to evaluate the ability of HA to reduce the onset of side effects due to radiotherapy. MATERIALS AND METHODS: In total, 180 women undergoing radiotherapy were randomized into two arms: controls and those treated with vaginal suppositories containing low-molecular-weight HA from day 1 of radiotherapy...
March 12, 2019: Oncology Research and Treatment
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"